

Pillar Biosciences, Inc. 9 Strathmore Rd Natick, MA 01760 (800) 514-9307 | www.pillarbiosci.com

Evaluation of the Pillar Biosciences oncoReveal[™] Solid Tumor v2 (oRSTv2) Application on the **Beckman Coulter Biomek NGeniuS System**

Joseph Goffreda¹, Sean Marris¹, Nicholas Lodato¹, Jeffrey Wilson², Yi Cao¹, Jamie Lim¹, Michael Montgomery¹, ShiPing Zou¹, Brian Wright¹, Zhaohui Wang¹

ABSTRACT

Introduction: The manual preparation of libraries for nextgeneration sequencing (NGS) can lead to high variance in library yield, quality, and turnaround time due to individual differences in pipetting technique and speed. To address this, we developed an application on Beckman Coulter Life Sciences Biomek NGeniuS Next Generation Library Prep System that automates the oncoReveal[™] Solid Tumor v2 (oRSTv2) research use only (RUO) panel library preparation workflow from DNA through indexed libraries. The oRSTv2 application enables the preparation of between 4 to 24 samples from input DNAs to final libraries with ~1 to 1.5 hours upfront hands-on time and ~5.5 to 7.5 hours of walkaway time. In this study, we evaluated the laboratory performance of the oRSTv2 application on the Biomek NGeniuS system.

Methods: Twenty (20) replicates of NA12878 (Coriell Institute) DNA samples and 22 moderately formalin-compromised positive DNA (ModfcDNA, Horizon Discovery) samples with an input of 19.35ng across three oRSTv2 application runs. Six (6) No-Template Controls (NTC) were also processed. Three (3) application runs performed on non-consecutive days, and contained 24, 16, and 8 libraries, respectively. The first run (24 libraries) was sequenced on an Illumina NextSeg[™] 550. Subsequent runs (16 and 8 libraries) were sequenced on an Illumina MiSeq[™]. Sequencing metrics and variants reported by PiVAT[®] (Pillar Variant Analysis Toolkit) software were analyzed.

Results: Total hands-on setup time ranged from 57 minutes to 1 hour 22 minutes. Total hands-off time ranged from 5 hours 44 minutes to 7 hours 27 minutes. Library yields averaged 50.67 nM and 35.95 nM for NA12878 and ModfcDNA samples, respectively. Effective on-target rate was above 90% for all replicates, with an average of 98.25% and 97.52% for NA12878 and ModfcDNA samples, respectively. Additionally, mapping rate was above 95% for all replicates, with an average of 99.45% and 99.02% for NA12878 and ModfcDNA samples, respectively. Overall, all NA12878 and ModfcDNA libraries had their expected variants called at the expected VAF. Cross-contamination was not observed in NTC replicates.

Conclusion: The Pillar oRSTv2 application on the Biomek NGeniuS Next Generation Library Prep System is capable of producing consistent high-quality libraries with minimal hands-on time and manual intervention. This system and our application will now provide clinical laboratories with low to moderate sample volume an opportunity to automate library preparation and expedite the delivery of NGS results.

APPLICATION DESIGN

	Manual ORSTv2 Application			
Sample Count	4-24 per batch	4-24 per batch	AKT1	с
Supported DNA Types & Input Mass	gDNA: 20-60ng FFPE: 20-80ng Severely degraded	FFPE: >=40ng	ALK ARAF	D
Estimated hands-on time	2 – 3.5 hours	1 – 1.5 hours	BRAF	El
Estimated hands-off time	3 hours 5.5 – 7.5 hours		CDKN2A CTNNB1	EI

Table 1 - Features of the oRSTv2 application.

App Setting	Description			
Mix beads during Exo digestion	Mixes AMPure XP beads during Exonuclease I digestion to reduce bead settling and sample processing time. If not selected, mixing will occur directly before gene-specific product purification. Allows the operator to enter in a name for the index plate being used in the batch.			
IndexPlate				
Indexing PCR Cycles	Allows the operator to set the number of indexing PCR cycles performed within a range of 6-10.			


	oRSTv2 Panel Info						
AKT1	CYSLTR2	FBXW7	GNAS	KEAP1	NTRK1	PTEN*	SMAD4
ALK	DDR2	FGFR1	H3F3A (H3-3A)	кіт	PDGFRA	PTPN11	SRSF2
ARAF	EGFR	FGFR2	HIST1H3B (H3C2)	KRAS	РІКЗСА	RAC1	STK11
BRAF	EIF1AX	FGFR3	HRAS	MAP2K1	PLCB4	RAF1	TERT
CDKN2A	ERBB2	GNA11	IDH1	MET	POLD1	RET	TP53
CTNNB1	ERBB4	GNAQ	IDH2	NRAS	POLE	SF3B1	TSHR

indicate full CDS coverage * Indicates full CDS with exception of exon 9, chr10; 89725157-89725229

	Gene	Variant ID	Genomic Position	Gene	Variant ID	Genomic Position
	EGFR	p.G719S	chr7:55241707-55241707	NRAS	p.Q61K	chr1:115256530- 115256530
		p.L858R	chr7:55259515-55259515	PDGFRA	p.Pro567=	chr4:55141055-55141055
		p.E746_A750del	chr7:55242465-55242479	PDGFRA	p.V824=	chr4:55152040-55152040
		p.T790M	chr7:55249071-55249071	PIK3CA	p.E545K	chr3:178936091- 178936091
		p.Q787=	chr7:55249063-55249063	PIK3CA	p.H1047R	chr3:178952085- 178952085
		N/A	chr7:55228053-55228053	PTEN	N/A	chr10:89720907-89720907
	KRAS	p.G12D	chr12:25398284-25398284	FGFR3	p.T651=	chr4:1807894-1807894
	-	p.G13D	chr12:25398281-25398281	KEAP1	p.L471=	chr19:10600442-10600442
		p.T1052=	chr12:133236000- 133236000	кіт	p.D816V	chr4:55599321-55599321
	POLE	p.A31S	chr12:133257837- 133257837	BRAF	p.V600E	chr7:140453136- 140453136
		N/A	chr12:133250118- 133250118	RET	p.L769=	chr10:43613843-43613843
		N/A	chr7:6426941-6426941	TERT	N/A	chr5:1295243-1295243
	NACI	N/A	chr7:6426953-6426953			


Table 4 - Clinically significant variants evaluated in the development of the oRSTv2 application.


¥




¹ Pillar Biosciences, Natick, MA; ² Beckman Coulter Life Sciences, Indianapolis, IN

RESULTS AND CONCLUSIONS







Gene BRAF

GER

GER

RAS

(RAS

NRAS PIK3CA

РІКЗСА

GFR

FGFR

GFR

GFR3


KEAP1


DGFRA

PDGFRA

OLE

OLE





Conclusions

1. Using the oRSTv2 application on the Biomek NGeniuS system, up to 24 libraries can be prepared with ~1 - 1.5 hours hands-on time and ~5.75 - 7.5 hours hands-off time (Figure 5). 2. The Biomek NGeniuS oRSTv2 application can produce high quality libraries (Figures 2-4, Table 5).

- 3. Resulting variant calls for libraries prepared via the oRSTv2 application were consistent with expected VAF %s (Table 5).
- 4. Combined with a rapid NGS platform, this automation system & application can potentially accelerate the delivery of next day tumor profiling results.



Table 5 – Average variant read frequency % for expected ModfcDNA and NA12878 variants

	HGVSC	Genomic Position	Expected VAF (%)	Hit Rate	Average VAF (%)
	c.1799T>A	chr7:140453136-140453136	10.5	22/22	11.94 <u>+</u> 0.91
	c.2155G>A	chr7:55241707-55241707	24.5	22/22	22.46 <u>+</u> 1.11
	c.2573T>G	chr7:55259515-55259515	3	22/22	3.62 <u>+</u> 0.47
	c.2447A>T	chr4:55599321-55599321	10	22/22	8.11 <u>+</u> 0.98
	c.35G>A	chr12:25398284-25398284	6	22/22	5.93 <u>+</u> 0.88
	c.38G>A	chr12:25398281-25398281	15	22/22	14.81 <u>+</u> 0.94
	c.181C>A	chr1:115256530-115256530	12.5	22/22	13.08 <u>+</u> 1.26
	c.1633G>A	chr3:178936091-178936091	9	22/22	7.34 <u>+</u> 0.58
	c.3140A>G	chr3:178952085-178952085	17.5	22/22	17.37 <u>+</u> 1.33
	c.2235_2249del	chr7:55242465-55242479	2	15/22*	2.14 <u>+</u> 0.42
	c.2369C>T	chr7:55249071-55249071	1	11/22*	1.09 + 0.33
		198/198			
	c.2361G>A	chr7:55249063-55249063	49.2	20/20	49.3 <u>+</u> 1.16
	c.1953G>A	chr4:1807894-1807894	99.5	20/20	98.79 <u>+</u> 0.15
	c.1413C>G	chr19:10600442-10600442	50	20/20	49.75 <u>+</u> 1.07
	c.1701A>G	chr4:55141055-55141055	99.9	20/20	99.5 <u>+</u> 0.17
	c.2472C>T	chr4:55152040-55152040	50	20/20	47.92 <u>+</u> 1.5
	c.3156G>A	chr12:133236000-133236000	99.7	20/20	99.11 <u>+</u> 0.12
	c.91G>T	chr12:133257837-133257837	48.5	20/20	49.73 <u>+</u> 1.15
	c.2307G>T	chr10:43613843-43613843	99.7	20/20	99.29 <u>+</u> 0.12
	c.1498+22A>T	chr7:55228053-55228053	99.7	20/20	98.47 <u>+</u> 0.33
	c.1359+43G>A	chr12:133250118-133250118	99.6	20/20	98.69 <u>+</u> 0.22
	c.1026+32T>G	chr10:89720907-89720907	48.6	20/20	48.33 <u>+</u> 2
	c.107+27C>T	chr7:6426941-6426941	51.5	20/20	49.35 <u>+</u> 0.8
	c.107+39C>T	chr7:6426953-6426953	50.8	20/20	49.26 <u>+</u> 0.89
	N/A	chr5:1295243-1295243	56.6	20/20	56.72 <u>+</u> 3.99
NA12878 overall hit rate					
		478/478			

w VAF cutoff in PiVAT software. Not included in overall hit rate analys